Tricida to Present at the Needham Virtual Healthcare Conference
01 Abril 2022 - 11:00AM
Tricida, Inc. (Nasdaq: TCDA) announced today that it will
present at the 21st Annual Needham Virtual Healthcare Conference on
Monday, April 11, 2022 at 10:30 am Pacific Time / 1:30 pm Eastern
Time. Tricida will provide a company overview, business update and
progress on its key initiatives.
A live webcast of the presentation will be accessible on the
Tricida website at IR.Tricida.com. An archive of the webcast will
be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the
development and commercialization of its investigational drug
candidate, veverimer, a non-absorbed, orally-administered polymer
designed to slow CKD progression in patients with metabolic
acidosis and CKD. Tricida is currently conducting a renal outcomes
clinical trial, VALOR-CKD, to determine if veverimer slows CKD
progression in patients with metabolic acidosis and CKD. Metabolic
acidosis is a condition commonly caused by CKD that is believed to
accelerate the progression of kidney deterioration. It is estimated
to pose a health risk to approximately 4.3 million patients with
CKD in the United States. There are currently no therapies approved
by the FDA to slow progression of kidney disease by correcting
chronic metabolic acidosis in patients with CKD.
For more information about Tricida, please
visit www.tricida.com.
Contact:
Jackie Cossmon, IRCTricida, Inc.Senior Vice President of
Investor Relations and CommunicationsIR@Tricida.com
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024
Notícias em tempo-real sobre Tricida Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de